 Calliditas Therapeutics NASDAQ: CALT has submitted a marketing application to the FDA seeking approval for Nefecon, an oral formulation targeting down-regulation of IgA1 for primary IgA Nephropathy IgAN. IgAN, also known as Bergers disease, is a kidney disease that occurs when an antibody called immunoglobulin A IgA builds up in the kidneys, resulting in hampering the kidneys ability to filter waste from the blood. 